Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT06010901 2024-01-23

A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

Phase 1 Unknown

75 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05028504 2023-12-27

ALTER-GO-020

Phase 2 Unknown

86 enrolled

Gynecological Cancer

NCT06062563 2023-10-02

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Phase NA Unknown

10 enrolled

EndocrineHead & Neck

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

NCT05783921 2023-07-28

A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Unknown

60 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05885399 2023-06-02

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Phase 2 Unknown

5 enrolled

CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT05400876 2023-02-14

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Phase 1/2 Unknown

92 enrolled

Lymphoid

Lymphoma

NCT05726175 2023-02-13

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Phase 2 Unknown

20 enrolled

Breast

Breast Neoplasms

NCT05680038 2023-01-11

Penpulimab in Maintenance Therapy in Lymphoma

Unknown

167 enrolled

Lymphoid

Lymphoma

NCT05519202 2022-08-29

Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer

Phase 2 Unknown

47 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05485350 2022-08-03

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

32 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05460481 2022-07-20

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Phase 2 Unknown

29 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05244993 2022-07-12

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Phase 2 Unknown

42 enrolled

Breast

Breast Neoplasm Female

NCT05319886 2022-05-20

AP

Unknown

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04970914 2022-03-08

ALTER-C003

Phase 2 Unknown

32 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Phase 2 Unknown

54 enrolled

Lymphoid

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT05265962 2022-03-04

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Phase 2 Unknown

85 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04952493 2022-01-28

Anlotinib or Penpulimab in Combination With RAI for DTC

Phase 2 Unknown

42 enrolled

Head & Neck

Thyroid Neoplasms

NCT05137171 2021-11-30

AK105 Combined With Anlotinib in Patients With Cervical Cancer

Phase 2 Unknown

36 enrolled

Gynecologic

Uterine Cervical Neoplasms

Clinical Trials

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

ALTER-GO-020

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Penpulimab in Maintenance Therapy in Lymphoma

Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

AP

ALTER-C003

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Anlotinib or Penpulimab in Combination With RAI for DTC

AK105 Combined With Anlotinib in Patients With Cervical Cancer